Apr 15 2010
The New LANCE Ultra cAMP Detection Kit, recently launched by PerkinElmer, can screen and profile G-protein coupled receptors (GPCRs).
This kit enables carrying out pharmacological studies related to the challenging receptors that are responsible for several diseases like neurodegenerative, cancer, inflammatory, and metabolic disorders.
PerkinElmer’s general manager and vice president, Drug Discovery and Research Reagent Solutions, Bio-discovery, Martina Bielefeld-Sévigny, informed that with the evolution of the drug discovery processes, the requirement for very sensitive and sturdy methods to measure GPCR responses is increasing. She added that the GPCRs account for more than 40% of drug targets currently. She revealed that these needs are met by the new detection kit.
This kit provides excellent signal-to-noise ratios and high efficiency by using the proprietary ULight emission dye of PerkinElmer. The kit is optimized for utilization in high as well as ultra-high throughput screening applications to detect and analyze protein activity during research.
Scientists are able detect low cAMP levels due to the added sensitivity of the kit, even without re-engineering cell lines resulting in saving of resources and time. A proven and simple TR-FRET protocol is used by this assay for accurate and easy adoption in many HTS applications that includes 1,536-well formats. This kit is able to maximize sensitivity in conditions of very low cAMP levels when high throughput assays are not able to create reproduced data.
Compared to other kits available in the market, this kit provides three times more sensitivity and uses 80% fewer cells at the least. This kit is a handy tool for potential therapeutics search purposes.
Source: http://www.perkinelmer.com